Novavax Inc

Most Recent

  • Novavax scientist working on COVID-19 vaccine
    Healthcare

    Novavax Vaccine Is Spearheaded by Institutional Investors

    As the Novavax COVID-19 vaccine enters the U.S. market, the people behind the company are coming into question. Who owns Novavax?
    By Rachel Curry
  • Novavax vaccine being scanned in laboratory
    Healthcare

    Novavax Combined Vaccine Explained, NVAX Stock Looks Iffy

    Novavax has a combined influenza and COVID-19 vaccine awaiting clinical trials right now. Is NVAX stock a buy or sell?
    By Rachel Curry
  • What is the Novavax Vaccine, and How NVAX Stock Reacted to Updates?
    Healthcare

    Novavax Inches Closer to COVID-19 Vaccine, Stock Reacts to Updates

    Novavax is a key player in the COVID-19 vaccine race. NVAX stock has reacted to vaccine updates. Will Novavax be able to compete with Pfizer and Moderna?
    By Ambrish Shah
  • Is Novavax NVAX Stock a Buy or Sell?
    Healthcare

    Is Novavax Stock a Good Buy at This Price?

    This year, Novavax stock has risen over 3,400 percent. Is NVAX stock a buy or sell at this price?
    By Ambrish Shah
  • uploads///Novavax RSV Pipeline
    Company & Industry Overviews

    Exploring Novavax’s Vaccine Candidates for RSV

    According to Novavax, ~64.0 million RSV infections occur every year on a global basis. The global cost of RSV exceeds $88.0 billion.

    By Kenneth Smith
  • uploads///marijuana covid
    Cannabis

    Could Certain Marijuana Strains Help Fight COVID-19?

    The cannabis industry is doing its own research amid COVID-19. Researchers discovered that marijuana might have properties to fight the coronavirus.

    By Sushree Mohanty
  • will novavax stock rally covid
    Healthcare

    Novavax Stock Jumps Due to COVID-19 Vaccine Trial Results

    Investors have poured on Novavax stock as the company races to bring a COVID-19 vaccine to the market.
    By Ruchi Gupta
  • uploads///laboratory _
    Healthcare

    Pfizer Soars Due to Hopes about a Coronavirus Vaccine

    Pfizer (NYSE:PFE) stock rose 2.4% in pre-market trading at 7:51 AM ET today. The company’s experimental COVID-19 vaccine showed positive results.

    By Ambrish Shah
  • uploads///ferry _
    Consumer

    Can You Still Get a Piece of Norwegian Cruise Line Stock?

    Today at 6:22 AM ET, Norwegian Cruise Line Holdings (NASDAQ:NCLH) stock rose 12% to $17.90 in the pre-market session. What can investors expect?

    By Ambrish Shah
  • uploads///cruise _
    Consumer

    Buy Carnival Stock before It Makes Another Big Move

    Today at 6:32 AM ET, Carnival (NYSE:CCL) stock rose 11% to $16.00 in the pre-market session. The company has been benefiting from positive developments.

    By Ambrish Shah
  • uploads///coronavirus _
    Healthcare

    Novavax Soared 20% on Coronavirus Vaccine Hopes

    Today at 4:37 AM ET, Novavax stock rose 20% to $55.40 in the pre-market session. The company started the Phase I study of NVX-CoV2373.

    By Ambrish Shah
  • uploads///ferry boat _
    Consumer

    Is Carnival Stock Worth Your Attention Right Now?

    Carnival stock rose 15.2% on Monday and closed at $14.72 with a market cap of $10.7 billion. The stock price rose due to hope about a COVID-19 vaccine.

    By Ambrish Shah
  • uploads///laboratory _
    Healthcare

    Coronavirus Vaccine: Novavax and Moderna Lead the Race

    Novavax stock rose almost 133% in the week ended May 15 and closed at $43.63. The stock has generated returns of 552% in the last 12 months.

    By Ambrish Shah
  • uploads///vaccine _
    Healthcare

    Novavax Rose 38% Due to $384 Million COVID-19 Funding

    Today at 4:30 AM ET, Novavax stock rose 38% to $33.74 in the pre-market session. The company received funding for its COVID-19 vaccine candidate.

    By Ambrish Shah
  • uploads///Graph
    Earnings Report

    Will the ResVax Vaccine Be Key Revenue Driver for Novavax?

    On February 28, Novavax (NVAX) issued a press release announcing results from the first-ever Phase 3 trial for PrepareTM.

    By Margaret Patrick
  • uploads///syringe _
    Earnings Report

    What Analysts Are Recommending for Novavax after Q1 Results

    Novavax (NVAX) reported first-quarter results on May 2.

    By Margaret Patrick
  • uploads///businessman _
    Company & Industry Overviews

    Why Novavax Is Tanking Today

    Today, Novavax (NVAX) is trading close to $0.70, which is about 67.13% lower than its previous closing price.

    By Margaret Patrick
  • uploads///fish oil _
    Company & Industry Overviews

    What Wall Street Recommends for Amarin and Novavax

    On February 22, Amarin (AMRN) closed at $19.87, 14% higher than its previous closing price and 746% higher than its 52-week low of $2.35.

    By Margaret Patrick
  • uploads///syringe _
    Company & Industry Overviews

    Gauging Analysts’ Expectations for Novavax and Peers in August

    Novavax has entered into a key grant agreement with the Bill and Melinda Gates Foundation, which is the current source of its revenue.

    By Kenneth Smith
  • uploads///dna _
    Company & Industry Overviews

    How Analysts View Agios Pharmaceuticals and Peers in March 2018

    Of the nine analysts covering Agios Pharmaceuticals (AGIO) in March 2018, one gave it a “strong buy” rating, and six gave it a “buy” rating.

    By Kenneth Smith
  • uploads///Novavax Analysts recommendations
    Company & Industry Overviews

    Inside Analysts’ Recommendations for Novavax in November 2017

    A clinical-stage biotech company, Novavax’s (NVAX) pipeline includes products for influenza, Ebola virus, and Zika virus. In November, two of seven analysts gave NVAX stock a “strong buy” rating.

    By Kenneth Smith
  • uploads///Chart  Segment
    Company & Industry Overviews

    How Are Eli Lilly’s Business Segments Performing?

    Eli Lilly and Co.’s (LLY) overall business is classified into two business segments—Human Pharmaceuticals and Animal Health.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Bristol-Myers Squibb’s 2Q16 Estimates: Expect Growth!

    Bristol-Myers Squibb (BMY) is expected to report revenue growth of over 11% to $4.7 billion in its 2Q16 results on July 28, 2016.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Incyte Continues Its Growth Spree in 2015

    Incyte is a biopharmaceutical company that’s focused on the discovery, development, and commercialization of oncology drugs.

    By Mike Benson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.